Barclays Maintains an 'Overweight' on Celgene (CELG); Stumble in Europe, But Expect Continued U.S. Growth

Go back to Barclays Maintains an 'Overweight' on Celgene (CELG); Stumble in Europe, But Expect Continued U.S. Growth